ImetelChat

Many thanks:


youtu.be/Dlv2jcS3bQ4?si=CtmFzwLzsuX41n5Y

https://m.youtube.com/watch?si=CtmFzwLz ... e=youtu.be

Been thinking about your last post. Here’ MAIA with an “elegant” drug with advantages at least in theory over Imetelstat and significant human assets like Sergei M. Gryaznov and Jerry Shay both of whom were once part of Geron. And yet… And yet, they seem to be way behind in clinical development and ...

CKTC, thanks as always for posting. I do wonder if the lag time for Imetelstat is much less of an issue with AML since the cell doubling time is measured in hours. Also the “non canonical” effects of Imetelstat, now known to be related to ferroptosis effects might be at play. Of course the subtext o...

https://www.youtube.com/watch?v=EfI-CqCMubw https://www.youtube.com/watch?v=EfI-CqCMubw Rami says ADCOM in April Other salient feature, Grade 3-4 neutropenia in 68 % (manageable and transient) but notably only 1% with febrile neutropenia. It’s a stretch and a guess but regarding the need for hospita...

Great dig, hope some on board can listen in and report back.

Ah, thanks RC, missed reviewing them.

https://www.youtube.com/watch?v=yglG0-C-1TY

Hat tip to Kaz, YMB. “Dismayed and surprised at the lack of QOL improvement with Luspatercept” in contrast to Imetelstat.

Has anyone seen any comments besides the X comments kindly referenced by RC? Usually there is a bunch of video interviews, articles post ASH. So far I have not seen much. Please post if you have. Thansk

give it a rest. I will start to limit unnecessarily repetitive posts.

Dr. S has a little over 2 weeks to keep his promise to update re oral agent development progress

LWS, give it a rest. I will start to limit unnecessarily repetitive posts.

We would have known last month if Geron were granted the honor of a plenary

You are not wrong, it did not.

True. Bluebird’s box warning was related to the risk of emergence of rare cancers. Fortunately, the grade 3 and 4 events with Imetelstat were not and appear to be reversible.

There has been some discussion and concern re grade 3 and 4 events which apparently were reversible and did not result in patient deaths. It appears however that the placebo group was also subject to these events although not all were cytopenic events. Will be interesting to hear about how many pati...

RC, thanks for posting this. Undoubted we will hear more. We should keep in mind that TI is a pretty high bar and just reducing the transfusion requirement albeit not to zero is an accomplishment. The rise of hemoglobin of 5 gms in many is important to keep in mind.

KT, thanks for your comments. I am actually ok with Dr. P’s editorial. He is after all an expert and was chosen perhaps because of the ties of the early Imet clinical heme studies to Mayo and Dr. T but undoubtedly also because of his experience, expertise and familiarity with Imetelstat (Mayo probab...

KT, I am defending no one but just making an observation. Dr. P has 52 pages of article cited on Pub Med going back over 20 years. It’s hard to find a prominent physician especially in academics that doesn’t have some tie to industry. After all that’s (with the exception of pure funding from foundat...

Interesting, thanks for posting Jay.